Clinical Research

Vianex S.A.

Address
Varibobi Street 8

Sponsor Overview

assignment
6
sponsored trials
science
0
molecules
location_city
1
research centre
public
1
country
person_search
1
investigator

Specializations

Healthy Volunteer Bioequivalence Research

Vianex S.A. conducts clinical research in healthy male and female volunteers to assess bioequivalence between its formulations and comparator medicines.

  • Oral solid dosage forms
  • Cross-over comparative studies
  • Fasting and fed conditions

This area reflects a focus on pharmaceutical equivalence and generic medicine development.

Myasthenia Gravis Treatment

The sponsor also funds research related to myasthenia gravis, a neuromuscular disorder requiring targeted symptomatic management.

  • Pyridostigmine bromide
  • Acetylcholinesterase inhibition
  • Neuromuscular transmission

Its clinical interest includes medicines used to support muscle strength and daily functional mobility in this condition.

Antidiabetic Therapy

Vianex S.A. is involved in research on empagliflozin, a therapy used in type 2 diabetes mellitus.

  • SGLT2 inhibition
  • Glycaemic control
  • Metabolic disease treatment

This therapeutic area links the sponsor to medicines addressing blood glucose regulation and broader cardiometabolic care.

Sponsored Trials

Trial Name Country Status
A Bioequivalence Study of Empagliflozin 25 mg Film-Coated Tablets in Healthy Volunteers Under Fasting ConditionsCzechia CzechiaNot Recruiting
A Randomized, Open-Label, Two-Period, Two-Treatment, Cross-Over Bioequivalence Study of Pyridostigmine Bromide 180 mg Tablets versus Prolonged-Release Pyridostigmine Bromide in Healthy VolunteersCzechia CzechiaNot Recruiting
A Randomized, Open-Label, Two-Period, Two-Treatment, Crossover Bioequivalence Study of Pyridostigmine Bromide 180 mg Tablets versus a Prolonged-Release Reference Product in Healthy Volunteers under Fed ConditionsCzechia CzechiaNot Recruiting
Bioequivalence Study of Pyridostigmine Bromide P.R. Tab 180 mg vs. Mestinon Retard 180 mg in Myasthenia Gravis Treatment Under Fasting ConditionsCzechia CzechiaNot Recruiting
Open‑label, randomized, single‑dose, two‑period crossover bioavailability study of Empagliflozin/Metformin (12.5 mg/1000 mg) versus Synjardy in healthy volunteers.Czechia CzechiaNot Yet Recruiting
Open‑label, randomized, two‑period crossover bioequivalence study of pyridostigmine bromide 180 mg prolonged‑release tablet versus reference product in healthy volunteers (myasthenia gravis therapy)Czechia CzechiaNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 0 total (0% not shared with other sponsors)

This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
100%
Return partnership rate
1 of 1 sites collaborated multiple times

This sponsor has worked with 1 site across their trial portfolio.

Therapeutic Focus

  • 1.
    Musculoskeletal Diseases4 trials
    238 other sponsors
  • 2.
    Cardiovascular Diseases1 trial
    359 other sponsors
  • 3.
    Hormonal diseases1 trial
    89 other sponsors

Partnered Research Centres

1 centre
location_city
assignment24
Cepha s.r.o.
Address
Komenskeho 19, Severni Predmesti, 323 00 Pilsen
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Vianex S.A..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.